Expanded Access Program for RP in Adults
← catalyst calendarSponsored by Ocugen (industry) · OCGN — their whole pipeline →.
Phase
—
Status
Available
Study type
Expanded access
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-27
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | — | When the study began enrolling | |
| Primary completion | — | The date the last participant is measured for the primary outcome — the readout window | |
| Study completion | — | The whole study's end, after follow-up | |
| First posted | 2024-08-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Retinitis Pigmentosa
Intervention
- Drug: OCU400
Related
OCGN's other studiesmost recently updated first
- Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD Phase 3 · Recruiting
- Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis Phase 1/2 · Active, not recruiting
- Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME) Phase 1 · Recruiting
- A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease Phase 2/3 · Active, not recruiting
- Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Phase 1/2 · Active, not recruiting
Permalink · OCGN's whole pipeline · Catalyst calendar · Every registered study · What changed